Martin G. Friedman
Directeur/Membre du Conseil chez JDS Therapeutics LLC
Profil
Martin G.
Friedman is currently a Director at JDS Therapeutics LLC and a Managing Member at Pharmakon Advisors LP since 2011.
Previously, he worked as a Principal at J.P.
Morgan Partners (BHCA) LP and Co-Head of US Life Sciences Banking at Merrill Lynch, Pierce, Fenner & Smith, Inc. He also served as Head of Merger & Acquisition & Collaborations at Novartis AG in 2005.
Mr. Friedman obtained his undergraduate degree from Columbia College (Illinois) and his MBA from Columbia Business School.
Postes actifs de Martin G. Friedman
| Sociétés | Poste | Début |
|---|---|---|
Pharmakon Advisors LP
 Pharmakon Advisors LP Investment ManagersFinance Pharmakon Advisors LP (Pharmakon Advisors) is an independent private equity/venture capital firm founded in 2009, by Pablo Gerardo Legorreta and Pedro Gonzalez de Cosio. The firm is headquartered in New York, US. | Private Equity Investor | 01/01/2011 |
JDS Therapeutics LLC
 JDS Therapeutics LLC Pharmaceuticals: MajorHealth Technology JDS Therapeutics LLC develops and commercializes healthcare products to physicians, healthcare-delivery networks, and other healthcare professionals. Its products include Relizen, Serenol, and pipeline. The firms pipeline drugs include treatment for polycystic ovary syndrome (PCOS), an oral treatment for type 2 diabetes leveraging a novel mechanism of action with established safety, and a novel insulin. The company was founded by Phillip M. Satow and Michael S. Satow in 2011 and is headquartered in Purchase, NY. | Directeur/Membre du Conseil | - |
Anciens postes connus de Martin G. Friedman
| Sociétés | Poste | Fin |
|---|---|---|
| NOVARTIS AG | Corporate Officer/Principal | 01/12/2005 |
J.P. Morgan Partners (BHCA) LP
 J.P. Morgan Partners (BHCA) LP Investment ManagersFinance J.P. Morgan Partners (BHCA) LP engages in venture capital, private equity and leveraged buyout business. The company was founded in 1999 and is based in New York, New York. | Corporate Officer/Principal | - |
Merrill Lynch, Pierce, Fenner & Smith, Inc.
 Merrill Lynch, Pierce, Fenner & Smith, Inc. Investment Banks/BrokersFinance Founded in 1958, Merrill Lynch Piece Fenner & Smith, Inc. is an SEC registered broker/dealer located in New York City. The firm is a subsidiary of BAC North America Holding Co. and their ultimate parent is Bank of America Corp. (NYSE BAC). | Corporate Officer/Principal | - |
Formation de Martin G. Friedman
| Columbia College (Illinois) | Undergraduate Degree |
| Columbia Business School | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| NOVARTIS AG | Health Technology |
| Entreprise privées | 4 |
|---|---|
Pharmakon Advisors LP
Pharmakon Advisors LP Investment ManagersFinance Pharmakon Advisors LP (Pharmakon Advisors) is an independent private equity/venture capital firm founded in 2009, by Pablo Gerardo Legorreta and Pedro Gonzalez de Cosio. The firm is headquartered in New York, US. | Finance |
Merrill Lynch, Pierce, Fenner & Smith, Inc.
Merrill Lynch, Pierce, Fenner & Smith, Inc. Investment Banks/BrokersFinance Founded in 1958, Merrill Lynch Piece Fenner & Smith, Inc. is an SEC registered broker/dealer located in New York City. The firm is a subsidiary of BAC North America Holding Co. and their ultimate parent is Bank of America Corp. (NYSE BAC). | Finance |
J.P. Morgan Partners (BHCA) LP
J.P. Morgan Partners (BHCA) LP Investment ManagersFinance J.P. Morgan Partners (BHCA) LP engages in venture capital, private equity and leveraged buyout business. The company was founded in 1999 and is based in New York, New York. | Finance |
JDS Therapeutics LLC
JDS Therapeutics LLC Pharmaceuticals: MajorHealth Technology JDS Therapeutics LLC develops and commercializes healthcare products to physicians, healthcare-delivery networks, and other healthcare professionals. Its products include Relizen, Serenol, and pipeline. The firms pipeline drugs include treatment for polycystic ovary syndrome (PCOS), an oral treatment for type 2 diabetes leveraging a novel mechanism of action with established safety, and a novel insulin. The company was founded by Phillip M. Satow and Michael S. Satow in 2011 and is headquartered in Purchase, NY. | Health Technology |
